These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34262161)

  • 1. Ocular benzalkonium chloride exposure: problems and solutions.
    Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
    Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
    Nagstrup AH
    Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
    Wu JH; Wang TH; Huang JY; Su CC
    J Ocul Pharmacol Ther; 2021 Dec; 37(10):556-564. PubMed ID: 34610257
    [No Abstract]   [Full Text] [Related]  

  • 5. Preservatives in glaucoma medication.
    Steven DW; Alaghband P; Lim KS
    Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glaucoma therapy and ocular surface disease: current literature and recommendations.
    Anwar Z; Wellik SR; Galor A
    Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
    Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
    Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservatives and ocular surface disease: A review.
    Kahook MY; Rapuano CJ; Messmer EM; Radcliffe NM; Galor A; Baudouin C
    Ocul Surf; 2024 Aug; 34():213-224. PubMed ID: 39098762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
    Ammar DA; Noecker RJ; Kahook MY
    Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patients.
    Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
    Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of common ophthalmic preservatives on ocular health.
    Noecker R
    Adv Ther; 2001; 18(5):205-15. PubMed ID: 11783457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations.
    Hsu KH; Gupta K; Nayaka H; Donthi A; Kaul S; Chauhan A
    Pharm Res; 2017 Dec; 34(12):2862-2872. PubMed ID: 29067592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservatives in eyedrops: the good, the bad and the ugly.
    Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
    Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
    Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
    Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study.
    Boimer C; Birt CM
    J Glaucoma; 2013 Dec; 22(9):730-5. PubMed ID: 23524856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation.
    Hsu KH; Chauhan A
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):30-8. PubMed ID: 26459089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
    Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
    Br J Ophthalmol; 2021 Jan; 105(1):141-148. PubMed ID: 31383648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.